Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
biotech IPO
Podcast
GSK’s first lung cancer approval, a new IPO path and more
This week on “The Top Line”: GSK’s lung cancer approval, an unusual IPO strategy and a push to update animal testing rules.
Ayla Ellison
Jul 24, 2026 9:42am
Generic tariffs, Samsung Bio, HK IPO—Fierce Pharma Asia
Jul 24, 2026 9:00am
GSK-Hansoh, Merck-Kelun, AZ-Dizal—Fierce Pharma Asia
Jul 17, 2026 9:38am
Fierce Biotech
Avalyn brings in $300M from oversized IPO
Apr 30, 2026 3:18am
Merck, Zai Lab, Kailera-Hengrui—Fierce Pharma Asia
Apr 24, 2026 8:22am
Fierce Biotech
Avalyn aims for $182M IPO to fund ph. 3 trials of lung drugs
Apr 24, 2026 7:08am
